KARI DEBOO: Open Payments
NPI 1780963538 · MISSOULA, MT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$914 in 48 payments from 12 companies in 2025. Trend: 2023 $342 · 2024 $718 · 2025 $914
Food & beverage: $914
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 17 | $237 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $148 |
| Janssen Biotech, Inc. | 4 | $111 |
| Madrigal Pharmaceuticals | 3 | $82 |
| Regeneron Healthcare Solutions, Inc. | 3 | $57 |
| Aimmune Therapeutics, Inc. | 3 | $54 |
| PFIZER INC. | 3 | $53 |
| ORPHALAN INC | 2 | $46 |
| Lilly USA, LLC | 2 | $37 |
| Celltrion USA Inc. | 2 | $32 |
Products named: TREMFYA, SKYRIZI, ENTYVIO, REZDIFFRA, DUPIXENT, VIBERZI, VOWST, CUVRIOR.
Industry payments across MT — which companies pay providers there.
